

Napa Parinyanitikul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8953108/publications.pdf>

Version: 2024-02-01

26
papers

208
citations

1307543

7
h-index

1058452

14
g-index

26
all docs

26
docs citations

26
times ranked

569
citing authors

#	ARTICLE	IF	CITATIONS
1	Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. <i>Cancer Reports</i> , 2022, 5, e1575.	1.4	5
2	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. <i>JCO Precision Oncology</i> , 2022, 6, e2000368.	3.0	9
3	An open-label, randomized, controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12099-12099.	1.6	0
4	Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14557-e14557.	1.6	0
5	Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098546.	3.2	1
6	What is the best systemic treatment for newly diagnosed inflammatory breast cancer?—a narrative review. <i>Chinese Clinical Oncology</i> , 2021, 10, 55-55.	1.2	1
7	Rate of complete chemotherapy as planned with comprehensive geriatric assessment guided intervention among vulnerable elderly cancer patients: A randomized-open-label study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24021-e24021.	1.6	0
8	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. <i>PeerJ</i> , 2019, 7, e6501.	2.0	18
9	Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 399-412.	4.1	9
10	Prognostic significance of cyclin B1 expression plus clinicopathologic features in hormonal positive, HER2 negative early breast cancer in King Chulalongkorn Memorial Hospital During 2010-2015.. <i>Journal of Global Oncology</i> , 2019, 5, 75-75.	0.5	0
11	Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. <i>Supportive Care in Cancer</i> , 2018, 26, 2471-2477.	2.2	12
12	A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 467-467.	1.6	0
13	Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12069-12069.	1.6	0
14	Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10019-10019.	1.6	0
15	Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration. <i>Asian Biomedicine</i> , 2017, 10, 371-377.	0.3	3
16	Feasibility of withholding dexamethasone premedication in patients not experiencing two previous cycles of weekly paclitaxel related infusion hypersensitivity reaction.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21634-e21634.	1.6	1
17	The cost-effectiveness analysis of EGFR mutation test for management of advanced non-small cell lung cancer in Thailand.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20636-e20636.	1.6	0
18	The accuracy of carboplatin area under the curve (AUC) estimated by Calvert formula using Cockcroft-Gault formula and Thai eGFR in Thai cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14017-e14017.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. <i>Clinical Breast Cancer</i> , 2015, 15, 153-160.	2.4	33
20	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614.	1.8	34
21	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014, 5, 745-753.	2.5	46
22	Prevalence of KRAS gene mutation in ampullary cancer in Thai patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15175-e15175.	1.6	2
23	Analysis of KRT14 and SFTPB expression by immunohistochemistry method in squamous cell carcinoma of lung and head-neck cancer tissue.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22127-e22127.	1.6	0
24	Effect of adjuvant trastuzumab (T) among patients treated with neoadjuvant T-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 644-644.	1.6	0
25	Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 378-384.	2.4	32
26	Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. <i>Journal of Breast Cancer</i> , 0, 25, .	1.9	2